Association of metformin exposure with oncological outcomes in BCG-treated non-muscle-invasive bladder cancer: a three-arm retrospective cohort study

医学 二甲双胍 回顾性队列研究 内科学 比例危险模型 相伴的 糖尿病 膀胱癌 共病 养生 队列 体质指数 队列研究 2型糖尿病 肿瘤科 外科 癌症 泌尿科 中止 危险系数 生存分析 2型糖尿病 多元分析 疾病 化疗 优势比
作者
Ali Nebioğlu,Cuma Aytekin,Ahmet Turhan,Didem Derici Yıldırım,Hasan Erdal Doruk
出处
期刊:BMC Urology [BioMed Central]
标识
DOI:10.1186/s12894-026-02370-4
摘要

To evaluate the association between metformin exposure and oncological outcomes in bacillus Calmette–Guérin (BCG)-treated non-muscle-invasive bladder cancer (NMIBC) using a three-arm cohort design. Because all metformin-exposed patients were diabetic, the study was not designed to establish a direct antitumor effect of metformin. This retrospective cohort included 624 patients with NMIBC treated with transurethral resection and intravesical BCG. Patients were classified as diabetic metformin users ( n =147), diabetic non-metformin users ( n =89), or non-diabetic patients ( n =388). Diabetes was defined as a previously documented diagnosis of type 2 diabetes mellitus and/or current antidiabetic therapy; patients with type 1 diabetes were excluded. Metformin exposure was defined as use concurrent with the BCG treatment period. The BCG regimen comprised 6 weekly induction instillations with maintenance instillations in eligible patients; no concomitant intravesical chemotherapy was administered. Recurrence-free survival (RFS), progression-free survival (PFS), and overall survival (OS) were assessed using Kaplan–Meier analysis, log-rank tests, and multivariable Cox regression adjusted for clinicopathological and treatment-related covariates. A propensity-score matched sensitivity analysis comparing diabetic metformin users with diabetic non-metformin users was also performed. The median follow-up was 64.8 months. Diabetic patients were older and had higher body mass index and Charlson comorbidity index values than non-diabetic patients. Among diabetic patients with available data, median HbA1c was 7.85% (interquartile range 6.9–8.5) in metformin users and 7.45% (6.7–8.5) in non-metformin users; the median metformin dose was 1500 mg/day (range 500–2550). Tumor-related variables were broadly comparable, although T1 disease was more frequent in non-diabetic patients. During follow-up, 166 recurrences, 52 progressions, and 224 deaths occurred. Recurrence rates were 25.9%, 37.1%, and 24.5% in the metformin, diabetic non-metformin, and non-diabetic groups, respectively; corresponding 5-year RFS rates were 79.4%, 65.6%, and 79.1% ( p =0.066). Progression rates were 6.8%, 16.9%, and 7.0%, with 5-year PFS rates of 97.6%, 92.7%, and 96.5% ( p =0.007). OS differed significantly, favoring non-diabetic patients ( p <0.001). Multivariable Cox analysis did not confirm metformin exposure as an independent protective factor. In the propensity-matched analysis (78 pairs), metformin use was associated with lower progression risk (HR 0.32, 95% CI 0.12–0.88; p =0.028) and a non-significant trend toward lower recurrence (HR 0.62, 95% CI 0.35–1.09; p =0.095), with no difference in overall survival (HR 1.09, 95% CI 0.73–1.62; p =0.685). In BCG-treated NMIBC, metformin-exposed diabetic patients showed progression rates comparable to non-diabetic patients and lower than diabetic non-metformin users, an association that persisted in a propensity-matched sensitivity analysis. Because all metformin-exposed patients were diabetic, a direct antitumor effect of metformin cannot be established. Prospective studies incorporating diabetes severity, glycemic control, treatment duration, and adherence are warranted.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
JamesPei的应助被无心的画笔采纳,获得10
1秒前
李李李发布了新的文献求助10
1秒前
深情安青的应助被gyq采纳,获得10
1秒前
1秒前
SciGPT的应助被YAAH采纳,获得10
1秒前
沉默的亦竹完成签到,获得积分10
1秒前
vvkaway完成签到,获得积分10
2秒前
哈哈哈发布了新的文献求助10
2秒前
久某完成签到,获得积分10
2秒前
mary发布了新的文献求助10
2秒前
3秒前
挚友发布了新的文献求助10
3秒前
SciGPT的应助被dgb采纳,获得10
3秒前
quw88888发布了新的文献求助10
3秒前
3秒前
ganyanhui发布了新的文献求助10
4秒前
完美世界的应助被友好元槐采纳,获得10
4秒前
汉堡包的应助被可可采纳,获得10
4秒前
4秒前
小二郎的应助被卓尔不群金良采纳,获得10
5秒前
5秒前
充电宝的应助被chiyudawang采纳,获得10
5秒前
虚幻雪一发布了新的文献求助10
5秒前
桐桐的应助被lalala采纳,获得10
6秒前
蓝意发布了新的文献求助10
6秒前
6秒前
molihuakai的应助被彪壮的绮烟采纳,获得10
7秒前
Maestro_S的应助被张若虚采纳,获得10
7秒前
7秒前
落后夏之发布了新的文献求助10
8秒前
molihuakai的应助被嘟噜采纳,获得10
8秒前
8秒前
Cc发布了新的文献求助10
8秒前
LL完成签到,获得积分10
9秒前
9秒前
Akim的应助被ZND采纳,获得10
9秒前
洋芋大大王完成签到 ,获得积分10
9秒前
Hao发布了新的文献求助10
9秒前
10秒前
ganyanhui完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178203
求助须知:如何正确求助?哪些是违规求助? 9568998
关于积分的说明 21802098
捐赠科研通 7773088
什么是DOI,文献DOI怎么找? 3432711
关于科研通互助平台的介绍 2556748
邀请新用户注册赠送积分活动 2478259